Biotest Receives Approval To Market Transfusion Reagents In Canada

A full line of monoclonal and polyclonal anti-sera and red blood cell reagents now available

Biotest AG, a global pharmaceutical and diagnostics company, has been cleared by Health Canada to market a comprehensive line of transfusion diagnostic reagents for blood compatibility testing. The Biotest reagents are available through RWR Scientific in Ottawa and include: Seraclone Typing and Rare Antisera Reagents, Anti-Human-Globulin, and Red Cell reagents for Typing, Antibody Detection, and Identification.

"We are pleased with the opportunity to expand our transfusion business in Canada with a full line of quality traditional transfusion reagents" says Bill Weiss, President of Biotest USA. In addition to the traditional transfusion reagents, Biotest's fully automated instrument for transfusion diagnostics, Tango, was introduced last year in Canada and is currently marketed by Olympus Corporation. Joy Thomsen, Manager of Transfusion Technical Services adds, "The line of Biotest reagents creates another viable option for health care providers to choose from."

Biotest has 60 years of experience in the development and production of high quality products for the transfusion diagnostic market. In 1948, Biotest offered the first commercially available anti-D test serum. Then in 1983, the Paul Ehrlinch Institute granted its first license to Biotest for use of Seraclone monoclonal antibodies for blood grouping.

SOURCE: Biotest